Gabapentin
Product Images NDC 68387-404

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68387-404). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Keltman Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dc2d0eb8-figure-06 (Gabapentin 100mg Label)

Gabapentin 100 mg capsules packaging label from Keltman Pharmaceuticals, Inc. The label indicates 120 capsules per package with each capsule containing 100 mg of gabapentin. It includes the NDC number 68387-420-12, lot number A12110 1, and expiration date 1/2012. Manufacturer is Amneal Pharmaceuticals of NY, distributed by Keltman Pharmaceuticals, Inc.*

FDA Label Image

Dc2d0eb8-figure-07 (Gabapentin 300mg Label)

Label for Gabapentin 300mg capsules, generic Neurontin, with 30 capsules per package. The label displays the NDC 68387-410-30 and lists Keltman Pharmaceuticals Inc. as the distributor. It includes storage instructions, lot number B01010 1, expiration date 1/2012, and note that the product is Rx only. Manufactured by Amneal Pharmaceuticals of NY Hauppauge.*

FDA Label Image

Dc2d0eb8-figure-08 (Gabapentin 400mg Label)

Label for Gabapentin 400mg capsules by Keltman Pharmaceuticals Inc. The label indicates 60 capsules per bottle with each capsule containing 400mg of gabapentin. It includes lot number B08610 1 and an expiration date of 3/2012. Usage instructions and caution about federal law prohibiting transfer are also visible. Manufacturer is Amneal Pharmaceuticals of NY.*

FDA Label Image

Dc2d0eb8-figure-01 (Dc2d0eb8 Figure 01)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid moiety.*

FDA Label Image

Dc2d0eb8-figure-02 (Dc2d0eb8 Figure 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline through 8, with distinct 4-week dose titration and fixed dose periods. Gabapentin shows a marked decrease in pain scores compared to placebo, with statistical significance at p < 0.01 indicated for multiple time points.*

FDA Label Image

Dc2d0eb8-figure-03 (Dc2d0eb8 Figure 03)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis marks weeks, the y-axis mean pain score, showing a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin group scores decrease notably compared to the placebo group.*

FDA Label Image

Dc2d0eb8-figure-04 (Dc2d0eb8 Figure 04)

A bar chart displaying the percentage of responders at endpoint for Gabapentin (GBP) and placebo (PBO) across two studies. Study 1 compares PBO and GBP 3600 mg, showing 12% and 29% responders respectively. Study 2 compares PBO, GBP 1800 mg, and GBP 2400 mg, with responder percentages of 14%, 32%, and 34%. Statistical significance markers for p-values are indicated.*

FDA Label Image

Dc2d0eb8-figure-05 (Dc2d0eb8 Figure 05)

A scatter plot showing the percentage difference on the vertical axis against daily dose in milligrams on the horizontal axis. It compares three studies labeled a, b, and c, each represented by different colored squares, across daily doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.